



Adjusted Financial Tables

2021 & 2022 Q3 and 9-Month YTD

Explanatory Note Regarding Non-GAAP Financial Measures

Enovis has provided in the tables presented below financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures include adjusted net income from continuing operations, adjusted net income per diluted share from continuing operations, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization).

Adjusted net income from continuing operations and Adjusted net income per diluted share from continuing operations excludes restructuring and other charges, European Union Medical Device Regulation (“MDR”) and related costs, amortization of acquired intangibles, inventory step up costs, strategic transaction costs, insurance settlement (gain) loss, stock compensation costs, debt extinguishment costs, and gains and losses on the Company’s investments. Adjusted net income adjusts interest expense to reflect pro forma interest from the Company’s term loan facility under the Company’s current capital structure after giving effect to the completing of the refinancing transactions in connection with the Separation, and it includes the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments.

Adjusted EBITDA represents operating income from continuing operations excluding restructuring and other charges, MDR and related costs, amortization of acquired intangibles, inventory step up costs, strategic transaction costs, insurance settlement (gain) loss, stock-based compensation costs, and depreciation and amortization.

These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures to GAAP results has been provided in the financial tables included below.

Q3 2022

| | | | | | | | Remove | | | | | | | | | |
|--|-------------|-----------|---------------|-----------|---------|--------------|------------|---------|--------|----------------|------------|--|--|--|-------------------------------|-------------|
| | | | | | | | Investment | | | | | | | | | |
| | | | | | | | Activity & | | | | | | | | | |
| \$ in thousands | Enovis | Inventory | Restructuring | Strategic | Stock | Acquired | Insurance | Remove | Adjust | Adjusted | | | | | | |
| Q3 2022 | 10-Q | Step-up | & MDR | Costs | Comp | Amortization | Settlement | DiscOps | Income | Enovis | | | | | aEBITDA | |
| | | | | | | | | | Taxes | | | | | | | |
| Net sales | \$ 383,814 | | | | | | | | | \$ 383,814 | | | | | Operating loss | \$ (17,919) |
| Cost of sales | 167,990 | (2,061) | | | | | | | | 165,929 | | | | | Restructuring & other | 2,989 |
| Gross profit | 215,824 | | | | | | | | | 217,885 | 56.8% | | | | MDR | 3,600 |
| SG&A | 182,187 | | (3,600) | (8,146) | (7,205) | | | | | 163,236 | | | | | Strategic transaction costs | 8,146 |
| R&D | 15,599 | | | | | | | | | 15,599 | | | | | Stock compensation | 7,205 |
| Amortization of acquired intangibles | 31,993 | | | | | (31,993) | | | | - | | | | | Depr & other amortization | 18,159 |
| Insurance settlement loss | 975 | | | | | | (975) | | | - | | | | | Amort of acquired intangibles | 31,993 |
| Restructuring | 2,989 | | (2,989) | | | | | | | - | | | | | Insurance settlement gain | 975 |
| Operating (loss) income | (17,919) | | | | | | | | | 39,050 | | | | | Inventory step-up | 2,061 |
| Interest expense, net | 6,334 | | | | | | | (1,534) | | 4,800 | | | | | aEBITDA | \$ 57,209 |
| Loss on ESAB | 63,125 | | | | | | (63,125) | | | - | | | | | | |
| Gain on cost basis investment | (8,800) | | | | | | 8,800 | | | - | | | | | | |
| Other income | (300) | | | | | | 300 | | | - | | | | | | |
| (Loss) income before taxes | (78,278) | | | | | | | | | 34,250 | | | | | | |
| Income tax (benefit) expense | (12,329) | | | | | | | | 14,249 | 1,920 | 5.6% | | | | | |
| Loss from DiscOps | (527) | | | | | | | 527 | | - | | | | | | |
| NCI | 136 | | | | | | | | | 136 | | | | | | |
| Net (loss) income attributable to Enovis | \$ (66,612) | | | | | | | | | \$ 32,194 | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | shares | 54,463,199 | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | aEPS - diluted | \$ 0.59 | | | | | |

9-Month YTD 2022

| | | | | | | | Remove Investment Activity & Insurance Settlement | | | | Adjust Income Taxes | Adjusted Enovis | | | |
|--------------------------------------|----------------|----------------------|------------------------|--------------------|---------------|--------------------------|---|----------|-------------------|--|---------------------------|--------------------|-------|-------------------------------|-------------|
| \$ in thousands | Enovis 10-Q | Inventory Step-up | Restructuring & MDR | Strategic Costs | Stock Comp | Acquired Amortization | | Interest | Remove DiscOps | | | | | aEBITDA | |
| 9M 2022 | | | | | | | | | | | | | | | |
| Net sales | \$ 1,154,388 | | | | | | | | | | | \$ 1,154,388 | | Operating loss | \$ (42,993) |
| Cost of sales | 516,758 | (12,038) | (844) | | | | | | | | | 503,876 | | Restructuring & other | 8,497 |
| Gross profit | 637,630 | | | | | | | | | | | 650,512 | 56.4% | MDR | 10,648 |
| SG&A | 564,324 | | (10,648) | (32,549) | (21,734) | | | | | | | 499,393 | | Strategic transaction costs | 32,549 |
| R&D | 46,102 | | | | | | | | | | | 46,102 | | Stock compensation | 21,734 |
| Amortization of acquired intangibles | 94,603 | | | | | (94,603) | | | | | | - | | Depr & other amortization | 56,109 |
| Insurance settlement gain | (32,059) | | | | | | 32,059 | | | | | - | | Amort of acquired intangibles | 94,603 |
| Restructuring | 7,653 | | (7,653) | | | | | | | | | - | | Insurance settlement gain | (32,059) |
| Operating (loss) income | (42,993) | | | | | | | | | | | 105,017 | | Inventory step-up | 12,038 |
| Interest expense, net | 17,944 | | | | | | | (10,944) | | | | 7,000 | | aEBITDA | \$ 161,126 |
| Debt extinguishment charges | 20,104 | | | | | | | (20,104) | | | | - | | | |
| Gain on ESAB | (72,412) | | | | | | 72,412 | | | | | - | | | |
| Gain on cost basis investment | (8,800) | | | | | | 8,800 | | | | | - | | | |
| Other income | (300) | | | | | | 300 | | | | | - | | | |
| Income before taxes | 471 | | | | | | | | | | | 98,017 | | | |
| Income tax (benefit) expense | (16,176) | | | | | | | | | | 29,016 | 12,840 | 13.1% | | |
| Income from DiscOps | 10,163 | | | | | | | | (10,163) | | | - | | | |
| NCI | 1,499 | | | | | | | | (966) | | | 533 | | | |
| Net income attributable to Enovis | \$ 25,311 | | | | | | | | | | | \$ 84,644 | | | |
| | | | | | | | | | | | | | | shares | 54,460,003 |
| | | | | | | | | | | | | | | aEPS - diluted | \$ 1.55 |

Q3 2021

| \$ in thousands | Enovis | Inventory | Restructuring | Strategic | Stock | Acquired | | Remove | Adjust | Adjusted | | | |
|--------------------------------------|------------|-----------|---------------|-----------|---------|--------------|----------|----------|--------|------------|-------|-------------------------------|-------------|
| Q3 2021 | 10-Q | Step-up | & MDR | Costs | Comp | Amortization | Interest | DiscOps | Income | Enovis | | aEBITDA | |
| | | | | | | | | | Taxes | | | | |
| Net sales | \$ 359,923 | | | | | | | | | \$ 359,923 | | Operating loss | \$ (16,107) |
| Cost of sales | 162,047 | (1,410) | | | | | | | | 160,637 | | Restructuring & other | 2,230 |
| Gross profit | 197,876 | | | | | | | | | 199,286 | 55.4% | MDR | 1,902 |
| SG&A | 168,270 | | (1,902) | (11,362) | (6,253) | | | | | 148,753 | | Strategic transaction costs | 11,362 |
| R&D | 12,458 | | | | | | | | | 12,458 | | Stock compensation | 6,253 |
| Amortization of acquired intangibles | 31,025 | | | | | (31,025) | | | | - | | Depr & other amortization | 18,397 |
| Restructuring | 2,230 | | (2,230) | | | | | | | - | | Amort of acquired intangibles | 31,025 |
| Operating (loss) income | (16,107) | | | | | | | | | 38,075 | | Inventory step-up | 1,410 |
| Interest expense, net | 4,122 | | | | | | (3,122) | | | 1,000 | | aEBITDA | \$ 56,472 |
| (Loss) income before taxes | (20,229) | | | | | | | | | 37,075 | | | |
| Income tax (benefit) expense | (6,651) | | | | | | | | | 13,280 | 35.8% | | |
| Income from DiscOps | 40,435 | | | | | | | (40,435) | 19,931 | - | | | |
| NCI | 1,009 | | | | | | | (818) | | 191 | | | |
| Net income attributable to Enovis | \$ 25,848 | | | | | | | | | \$ 23,604 | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | shares | 53,722,365 |

9-Month YTD 2021

| \$ in thousands | Enovis | Inventory | Restructuring | Strategic | Stock | Acquired | | Remove | Adjust | Adjusted | | | |
|--------------------------------------|--------------|-----------|---------------|-----------|----------|--------------|----------|-----------|--------|----------------|-------|-------------------------------|-------------|
| 9M 2021 | 10-Q | Step-up | & MDR | Costs | Comp | Amortization | Interest | DiscOps | Income | Enovis | | aEBITDA | |
| | | | | | | | | | Taxes | | | | |
| Net sales | \$ 1,027,130 | | | | | | | | | \$ 1,027,130 | | Operating loss | \$ (44,589) |
| Cost of sales | 457,379 | (3,707) | | | | | | | | 453,672 | | Restructuring & other | 5,193 |
| Gross profit | 569,751 | | | | | | | | | 573,458 | 55.8% | MDR | 5,574 |
| SG&A | 487,220 | | (5,574) | (15,780) | (19,000) | | | | | 446,866 | | Strategic transaction costs | 15,780 |
| R&D | 33,860 | | | | | | | | | 33,860 | | Stock compensation | 19,000 |
| Amortization of acquired intangibles | 88,067 | | | | | (88,067) | | | | - | | Depr & other amortization | 51,639 |
| Restructuring | 5,193 | | (5,193) | | | | | | | - | | Amort of acquired intangibles | 88,067 |
| Operating (loss) income | (44,589) | | | | | | | | | 92,732 | | Inventory step-up | 3,707 |
| Interest expense, net | 22,751 | | | | | | (19,751) | | | 3,000 | | aEBITDA | \$ 144,371 |
| Debt extinguishment charges | 29,870 | | | | | | (29,870) | | | - | | | |
| (Loss) income before taxes | (97,210) | | | | | | | | | 89,732 | | | |
| Income tax (benefit) expense | (9,651) | | | | | | | | 40,847 | 31,196 | 34.8% | | |
| Income from DiscOps | 164,358 | | | | | | | (164,358) | | - | | | |
| NCI | 3,235 | | | | | | | (2,399) | | 836 | | | |
| Net income attributable to Enovis | \$ 73,564 | | | | | | | | | \$ 57,700 | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | shares | | 50,966,131 | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | aEPS - diluted | | \$ 1.13 | |